Vinge has advised Röko AB (publ) (“Röko”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on March 4, 2025 and the first day of trading is March 11, 2025.

The offering price was SEK 2,048 per class B share, corresponding to a total market value for all shares in Röko of approximately SEK 29.95 billion. The total value of the offering amounts to approximately SEK 5,284 million.

Röko is a Sweden-based serial acquirer that has completed 28 platform acquisitions in a variety of industries across Europe. The company's ambition is to be the perpetual owner of small and medium-sized businesses. Historically, Röko has primarily acquired small and medium-sized businesses headquartered in the Nordics and Northern Europe. Röko's organization has more than 100 years of combined experience working with founder- and entrepreneur-led companies in a wide range of industries and the individuals in executive management positions have worked at the company since its first year of operation.

Vinge’s team primarily consisted of Linnéa Sellström, Jesper Schönbeck, Erik Sjöman, Lorin Arabi, Annie Fällström, Michaela Ådén, Karin Karsten, Louise Nässén and Lovisa Jonassen (Capital Markets and Public M&A), Victor Ericsson, Emelie Svanberg, Erik Kochbati, Marcus Svärd and Ellenor Eckerborn (Corporate Tax), Helena Göransson, Nour Makie and William Carlberg Johansson (Financing), Nicklas Thorgerzon, Martin Boström and Elis Allmark (Commercial agreements, IT and GDPR) Johan Gavelin (Intellectual Property), Gulestan Ali (Regulatory) as well as Louisa Fagarasan (Employment).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026